GameChangers: Zilebesiran – A New Hypertension Treatment
GameChangers: Zilebesiran – A New Hypertension Treatment
Injectable, long-acting therapy is a new frontier for hypertension management. Join host, Geoff Wall, as he evaluates zilebesiran, a hepatic angiotensinogen blocker for blood pressure control for up to six months.
THE GAMECHANGER: Zilebesiran blocks the final production of angiotensinogen at the hepatic level making it safer from a renal perspective than the ACEis or ARBs. A single subcutaneous injection provides therapy for up to six months.
Upon successful completion of this course, learners should be able to:
1. Describe the mechanism of action of Zilebesiran
2. Discuss possible advantages and disadvantages of this drug in the treatment of hypertension
Geoffrey C. Wall, PharmD, FCCP, BCPS, CG
Professor of Clinical Sciences
Drake University College of Pharmacy and Health Sciences
Dr. Wall is a member of the Janssen Speaker’s Bureau. All relevant financial relationships have been mitigated.
Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Release Date: October 16, 2023
Planned Expiration Date: October 16, 2024
Copyright 2023, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.
CEImpact is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Obtain CPE credit by completing the course, followed by the exam and evaluation (if applicable). Once successfully completed, your course will appear in your Completed Courses tab. Access your CPE statement of credit at www.MyCPEMonitor.net.
¹CEImpact provides you with two (2) opportunities to complete the exam. The learner will not receive CPE credit after two failed attempts.
Additional information
| Duration | 0h 30m |
|---|---|
| Topic Designator | Disease State/Drug Therapy |
| ACPE | Yes |
| ACPE Topic | 01 Drug Therapy |
| Role | Pharmacist |
| Media-Type | Podcast |
| Release Date | 10/16/23 |
| CEUs | 0.05 |
| Rating | 4 |
| ACPE Number | 0107-0000-23-323-H01-P |
